Treatment of intrabony defects

Comparative evaluation of Platelet Rich Fibrin (PRF) and Titanium-Platelet Rich Fibrin (T-PRF) in the Treatment of Intrabony defects using 1% Metformin gel - A Clinical Study. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/057143

Enrollment

Registered

2023-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: TPRF(Titanium Platelet Rich Fibrin): Titanium Platelet Rich Fibrin with 1% Metformin Gel One and half Years Control Intervention1: PRF (Platelet Rich Fibrin): PLATELET RICH FIBRIN WITH

Eligibility

Inclusion criteria

Inclusion criteria: 1.Apparently healthy individuals. 2. Presence of Intrabony defect (IBD) depth =3 mm and interproximal probing depth (PD) =5 mm after phase I therapy.

Exclusion criteria

Exclusion criteria: 1. HISTORY OF : Aggressive Periodontitis. Smoking and tobacco use. Systemic conditions known to affect the periodontal status. Medications known to affect the gingival condition 2. Pregnant or lactating women. 3. Hematological disorders and insufficient platelet count after re-evaluation of Phase I therapy.

Design outcomes

Primary

Measure	Time frame
clinical outcome assessment. 1. PD- Probing Depth 2. RAL- Relative Attachment Level 3. GML – Gingival Marginal Level Timepoint: Baseline, 3 months and 6 months	—

Secondary

Measure	Time frame
radiographic parameters 1. Level of alveolar crest 2. Base of Intra Bony Defect 3. Defect fillTimepoint: All parameters are assessed at 0,3 & 6 months interval.	—

Countries

India

Contacts

Public ContactRaaja Sreepathy CS

Sri Venkateswara Dental College and Hospital

drshanpriya@gmail.com9003286399

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026